BioCentury | Jan 9, 2021
Product Development

Possible factors behind Sarepta’s DMD miss

...in programs through its 2019 acquisition of Myonexus Therapeutics Inc....
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...and Ohio State University professor Zhiwei Hu. Co-founder and CEO Bruce Halpryn was COO of Myonexus Therapeutics Inc....
BioCentury | Jun 8, 2020
Product Development

Sarepta heading toward pivotal trial of first limb-girdle muscular dystrophy gene therapy

...other types of LGMD. Sarepta obtained the LGMD pipeline via its acquisition last year of Myonexus Therapeutics Inc....
BioCentury | Dec 3, 2019
Company News

Astellas adds new focus area via $3B takeout of gene therapy company Audentes

...with small molecules for muscle diseases. Other gene therapy company takeouts announced this year include Myonexus Therapeutics Inc.'s...
BioCentury | Oct 4, 2019
Clinical News

Limb-girdle muscular dystrophy gene therapy data lift Sarepta

...kinase data revealed in February helped inform Sarepta’s decision to exercise its option to buy Myonexus Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...Inc. ( NYSE:MRK) Immune Design Corp. 2/21/19 $300.0 NA NA $300.0 Sarepta Therapeutics Inc. (NASDAQ:SRPT) Myonexus Therapeutics Inc....
BioCentury | Mar 6, 2019
Financial News

Follow-on roundup: Ascendis, Sarepta

...lost $16.54 (11%) to $132.25 on Wednesday. Last week, Sarepta exercised its option to acquire Myonexus Therapeutics Inc....
...limb-girdle muscular dystrophy (see "On Strength of First LGMD Data, Sarepta Exercises Option to Buy Myonexus"...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

...Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a...
...includes other exon-skipping therapies and gene therapies for DMD. Its microdystrophin gene therapy and the Myonexus...
...sarcoglycan γ Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Myonexus Therapeutics Inc. (New Albany, Ohio) Business: Musculoskeletal Paul Bonanos MYO-101 Myonexus Therapeutics Inc. Sarepta...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

...Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a...
...includes other exon-skipping therapies and gene therapies for DMD. Its microdystrophin gene therapy and the Myonexus...
...DYSF - Dysferlin; SGCA - sarcoglycan α; SGCB - sarcoglycan β; SGCG - sarcoglycan γ Paul Bonanos MYO-101 Myonexus Therapeutics Inc. Sarepta...
BioCentury | Jun 5, 2018
Company News

Management tracks: Sarepta, Gilead

...its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc....
Items per page:
1 - 10 of 14
BioCentury | Jan 9, 2021
Product Development

Possible factors behind Sarepta’s DMD miss

...in programs through its 2019 acquisition of Myonexus Therapeutics Inc....
BioCentury | Jul 23, 2020
Deals

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

...and Ohio State University professor Zhiwei Hu. Co-founder and CEO Bruce Halpryn was COO of Myonexus Therapeutics Inc....
BioCentury | Jun 8, 2020
Product Development

Sarepta heading toward pivotal trial of first limb-girdle muscular dystrophy gene therapy

...other types of LGMD. Sarepta obtained the LGMD pipeline via its acquisition last year of Myonexus Therapeutics Inc....
BioCentury | Dec 3, 2019
Company News

Astellas adds new focus area via $3B takeout of gene therapy company Audentes

...with small molecules for muscle diseases. Other gene therapy company takeouts announced this year include Myonexus Therapeutics Inc.'s...
BioCentury | Oct 4, 2019
Clinical News

Limb-girdle muscular dystrophy gene therapy data lift Sarepta

...kinase data revealed in February helped inform Sarepta’s decision to exercise its option to buy Myonexus Therapeutics Inc....
BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...Inc. ( NYSE:MRK) Immune Design Corp. 2/21/19 $300.0 NA NA $300.0 Sarepta Therapeutics Inc. (NASDAQ:SRPT) Myonexus Therapeutics Inc....
BioCentury | Mar 6, 2019
Financial News

Follow-on roundup: Ascendis, Sarepta

...lost $16.54 (11%) to $132.25 on Wednesday. Last week, Sarepta exercised its option to acquire Myonexus Therapeutics Inc....
...limb-girdle muscular dystrophy (see "On Strength of First LGMD Data, Sarepta Exercises Option to Buy Myonexus"...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

...Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a...
...includes other exon-skipping therapies and gene therapies for DMD. Its microdystrophin gene therapy and the Myonexus...
...sarcoglycan γ Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Myonexus Therapeutics Inc. (New Albany, Ohio) Business: Musculoskeletal Paul Bonanos MYO-101 Myonexus Therapeutics Inc. Sarepta...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

...Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a...
...includes other exon-skipping therapies and gene therapies for DMD. Its microdystrophin gene therapy and the Myonexus...
...DYSF - Dysferlin; SGCA - sarcoglycan α; SGCB - sarcoglycan β; SGCG - sarcoglycan γ Paul Bonanos MYO-101 Myonexus Therapeutics Inc. Sarepta...
BioCentury | Jun 5, 2018
Company News

Management tracks: Sarepta, Gilead

...its newly created gene therapy unit. She will continue to serve as acting CSO at Myonexus Therapeutics Inc....
Items per page:
1 - 10 of 14